Company
Syndeavor Therapeutics
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Developing a small molecule inhibitor of ACSS2 for the treatment of TNBC and NSCLC.
Loading relationship preview
Company
Record updated 28 September 2026
Developing a small molecule inhibitor of ACSS2 for the treatment of TNBC and NSCLC.
A first look at Syndeavor Therapeutics’s connections in the VC Catalog database. Sign in with Google to open the interactive map.
Investor VC firms in this preview
VC firm names are a sample from VC Catalog’s database and may be incomplete. A database connection is not a guarantee of an introduction.